Hormone therapy

• Health & Medicine

Aromatase inhibitors cut breast cancer recurrence in younger patients

A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women. A study by Oxford University has found that aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in both younger and older women.

11 February 2022

• Science & Technology
• Health & Medicine

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference. Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer, according to findings presented at the ESMO conference.

19 September 2021

• Health & Medicine

Hormone therapy gets green light for advanced prostate cancer

Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option. Adults in England with advanced hormone-sensitive prostate cancer that’s spread to other parts of the body will now have a new treatment option.

14 September 2021

• Health & Medicine

New hormone treatment for advanced prostate cancer made available in England

Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England. Hormone treatment enzalutamide will now be offered as an alternative combined treatment option for some adults with prostate cancer on the NHS in England.

8 June 2021

• Health & Medicine

Prostate cancer hormone therapy not recommended for NHS in England

A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer. A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.

26 June 2020

• Health & Medicine

Hormone therapy now available for newly diagnosed prostate cancer in Scotland 

A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.   A hormone therapy has been approved for NHS use in Scotland for some people with newly diagnosed, advanced prostate cancer for the first time.  

20 January 2020

• Health & Medicine

Precision drug combo boosts survival in younger women with advanced breast cancer

Combining a targeted drug with hormone therapy extended the lives of pre-menopausal women with advanced breast cancer in a clinical trial. Combining a targeted drug with hormone therapy extended the lives of pre-menopausal women with advanced breast cancer in a clinical trial.

1 June 2019

• Health & Medicine

Breast cancer relapse test can predict treatment benefits, study suggests

Using a test that measures gene activity could help to tailor treatment for some women with early stage breast cancer, new research suggests. Using a test that measures gene activity could help to tailor treatment for some women with early stage breast cancer, new research suggests.

30 April 2019

• Health & Medicine

Advanced breast cancer drug combo approved for NHS in England

A new drug combo has been made available to some patients with advanced breast cancer on the NHS in England. A new drug combo has been made available to some patients with advanced breast cancer on the NHS in England.

3 April 2019

• Health & Medicine

Prostate cancer drug given initial ‘no’ for NHS in England

The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England. The prostate cancer drug abiraterone has been provisionally rejected as a first-line treatment on the NHS in England.

7 June 2018

• Health & Medicine

Apalutamide delays spread of certain prostate cancers in trial

An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results. An experimental hormone therapy delays the spread of prostate cancer that has stopped responding to standard treatment, according to new clinical trial results.

9 February 2018

• Health & Medicine

Giving prostate cancer drug earlier extends lives of men whose disease has spread

Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread. Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.

3 June 2017